Currently, the findings of imaging procedures used for detection or staging of prostate
cancer depend on morphology of lymph nodes or bone metabolism and do not always meet …

PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer
(PCa), but its clinical use was promptly extended to detection, staging and therapy response …

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …

Urea-based inhibitors of the prostate-specific membrane antigen (PSMA) represent low-
molecular-weight pepidomimetics showing the ability to image PSMA-expressing prostate …

Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner
represents a potentially powerful technology. Using prostate cancer as a model, we report …

Prostate specific membrane antigen (PSMA), is a unique membrane bound glycoprotein,
which is overexpressed manifold on prostate cancer as well as neovasculature of most of …

The prostate-specific membrane antigen (PSMA) is highly expressed on most prostate
cancer (PC) cells. Therefore, the targeting of PSMA has become increasingly important over …

177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using
inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration …

Targeting the prostate-specific membrane antigen (PSMA) with 68Ga-labeled and 18F-
labeled PET agents has become increasingly important in recent years. Imaging of …

In the past two decades, extensive efforts have been made to develop agents targeting
prostate-specific membrane antigen (PSMA) for prostate cancer imaging and therapy. To …